Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
100%
Progression Free Survival
87%
Neoplasm
86%
Overall Survival
82%
Disease
78%
Malignant Neoplasm
53%
Non Small Cell Lung Cancer
51%
Metastatic Colorectal Cancer
50%
Liver Cell Carcinoma
47%
Capecitabine
45%
Colorectal Carcinoma
40%
Pazopanib
39%
Monotherapy
37%
Cisplatin
35%
Docetaxel
35%
Adverse Event
34%
Regorafenib
34%
Phase I Trials
33%
Solid Malignant Neoplasm
32%
Pemetrexed
31%
Breast Cancer
30%
Retrospective Study
27%
Biological Marker
27%
Oxaliplatin
27%
Everolimus
26%
Sorafenib
26%
Phase II Trials
25%
Epidermal Growth Factor Receptor Kinase Inhibitor
23%
Paclitaxel
23%
Kidney Metastasis
20%
Melanoma
20%
Gemcitabine
19%
Primary Tumor
19%
Irinotecan
19%
Triple Negative Breast Cancer
18%
Cetuximab
17%
Disease Free Survival
17%
Epidermal Growth Factor Receptor
17%
Survival Rate
16%
Programmed Death 1 Ligand 1
16%
Disease Exacerbation
16%
Stomach Tumor
15%
Gastroenteropancreatic Neuroendocrine Tumor
15%
Prostate Cancer
15%
Protein Tyrosine Kinase
15%
Fibroblast Growth Factor Receptor 2
14%
Antitumor Activity
14%
Lung Cancer
13%
Combination Therapy
13%
Crizotinib
13%
Medicine and Dentistry
Abdominal Cancer
74%
Overall Survival
73%
Progression Free Survival
69%
Neoplasm
66%
Disease
49%
Non Small Cell Lung Cancer
44%
Prognostic Factor
43%
Hepatocellular Carcinoma
43%
Pazopanib
43%
Malignant Neoplasm
43%
Breast Cancer
37%
Melanoma
33%
Metastatic Carcinoma
31%
Primary Tumor
29%
Colorectal Carcinoma
29%
Connective Tissue Cancer
28%
Chemoradiotherapy
27%
Soft Tissue Sarcoma
24%
Phase II Trials
24%
Monotherapy
23%
Survival Rate
22%
Metastatic Melanoma
22%
Positron Emission Tomography
21%
Recurrence Free Survival
20%
Hazard Ratio
20%
Capecitabine
19%
Meningeal Carcinomatosis
19%
Gemcitabine
19%
Triple Negative Breast Cancer
19%
Surgery
18%
Cisplatin
18%
Metastatic Colorectal Cancer
17%
Biliary Tract Cancer
17%
Retrospective Study
17%
Programmed Death 1 Ligand 1
16%
Lung Cancer
16%
Paclitaxel
15%
Induction Chemotherapy
15%
In Vitro
15%
Radiation Therapy
15%
Arm
15%
Immunohistochemistry
15%
Multivariate Analysis
15%
Leiomyosarcoma
14%
Biological Marker
14%
Fibroblast Growth Factor Receptor 2
14%
BEZ235
13%
Fluorodeoxyglucose F 18
13%
Cancer Staging
13%
Transitional Cell Carcinoma
13%